Evidence map›Paper›PMID 34627166›Full record

ArticleBMC medical research methodology2021

Methods for the inclusion of real-world evidence in network meta-analysis.

David A Jenkins, Humaira Hussein, Reynaldo Martina, Pascale Dequen-O'Byrne, Keith R Abrams, Sylwia Bujkiewicz

Open access · goldAbstract readNetwork Meta-Analysis
In one paragraph

Article in BMC medical research methodology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 4 pooled it
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. A Review of Methods for Research Synthesis.Statistics in medicine · 2025
    Article
  7. Real-World Data and Causal Machine Learning to Enhance Drug Development.Therapeutic innovation & regulatory science · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Using Bayesian Evidence Synthesis Methods to Incorporate Real-World Evidence in Surrogate Endpoint Evaluation.Medical decision making : an international journal of the Society for Medical Decision Making · 2023
    Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

David A Jenkins *Biostatistics Research Group, Department of Health Sciences, University of Leicester, University Road, Leicester, LE1 7RH, UK.
Humaira Hussein *Biostatistics Research Group, Department of Health Sciences, University of Leicester, University Road, Leicester, LE1 7RH, UK. hh270@leicester.ac.uk.ORCID 0000-0003-4308-9423
Reynaldo MartinaBiostatistics Research Group, Department of Health Sciences, University of Leicester, University Road, Leicester, LE1 7RH, UK.
Pascale Dequen-O'ByrneBiostatistics Research Group, Department of Health Sciences, University of Leicester, University Road, Leicester, LE1 7RH, UK.
Keith R AbramsBiostatistics Research Group, Department of Health Sciences, University of Leicester, University Road, Leicester, LE1 7RH, UK.
Sylwia BujkiewiczBiostatistics Research Group, Department of Health Sciences, University of Leicester, University Road, Leicester, LE1 7RH, UK.
University of Leicester · GB

Funding

Medical Research Council MR/L009854/1Medical Research Council MR/R025223/1
6 · The paper itself

Abstract

backgroundNetwork Meta-Analysis (NMA) is a key component of submissions to reimbursement agencies world-wide, especially when there is limited direct head-to-head evidence for multiple technologies from randomised controlled trials (RCTs). Many NMAs include only data from RCTs. However, real-world evidence (RWE) is also becoming widely recognised as a valuable source of clinical data. This study aims to investigate methods for the inclusion of RWE in NMA and its impact on the level of uncertainty around the effectiveness estimates, with particular interest in effectiveness of fingolimod.

methodsA range of methods for inclusion of RWE in evidence synthesis were investigated by applying them to an illustrative example in relapsing remitting multiple sclerosis (RRMS). A literature search to identify RCTs and RWE evaluating treatments in RRMS was conducted. To assess the impact of inclusion of RWE on the effectiveness estimates, Bayesian hierarchical and adapted power prior models were applied. The effect of the inclusion of RWE was investigated by varying the degree of down weighting of this part of evidence by the use of a power prior.

resultsWhilst the inclusion of the RWE led to an increase in the level of uncertainty surrounding effect estimates in this example, this depended on the method of inclusion adopted for the RWE. 'Power prior' NMA model resulted in stable effect estimates for fingolimod yet increasing the width of the credible intervals with increasing weight given to RWE data. The hierarchical NMA models were effective in allowing for heterogeneity between study designs, however, this also increased the level of uncertainty.

conclusionThe 'power prior' method for the inclusion of RWE in NMAs indicates that the degree to which RWE is taken into account can have a significant impact on the overall level of uncertainty. The hierarchical modelling approach further allowed for accommodating differences between study types. Consequently, further work investigating both empirical evidence for biases associated with individual RWE studies and methods of elicitation from experts on the extent of such biases is warranted.

Indexed as

Research DesignBiasHumansNetwork meta-analysisRandomised controlled trialReal-world evidence

Identifiers

PMID34627166
PMCPMC8502389
OpenAlexW2804779582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.